Advertisement
Singapore markets closed
  • Straits Times Index

    3,348.87
    +12.28 (+0.37%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • Dow

    38,686.32
    +574.82 (+1.51%)
     
  • Nasdaq

    16,735.02
    -2.08 (-0.01%)
     
  • Bitcoin USD

    69,631.36
    +1,602.74 (+2.36%)
     
  • CMC Crypto 200

    1,494.08
    +26.15 (+1.78%)
     
  • FTSE 100

    8,294.43
    +19.05 (+0.23%)
     
  • Gold

    2,353.20
    +7.40 (+0.32%)
     
  • Crude Oil

    76.99
    0.00 (0.00%)
     
  • 10-Yr Bond

    4.4710
    -0.0430 (-0.95%)
     
  • Nikkei

    38,923.03
    +435.13 (+1.13%)
     
  • Hang Seng

    18,403.04
    +323.43 (+1.79%)
     
  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     
  • Jakarta Composite Index

    7,036.19
    +65.46 (+0.94%)
     
  • PSE Index

    6,470.74
    +37.64 (+0.59%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
Cellectis Inc.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, May 16, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

05/03/2024

99,955,535

87,891,239


For further information on Cellectis, please contact:

Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment